Search Results - "Stoller, R. G."

Pharmacokinetic Study of Pegylated Liposomal CKD-602 (S-CKD602) in Patients With Advanced Malignancies by Zamboni, WC, Strychor, S, Maruca, L, Ramalingam, S, Zamboni, BA, Wu, H, Friedland, DM, Edwards, RP, Stoller, RG, Belani, CP, Ramanathan, RK

“…S‐CKD602 is a pegylated liposomal formulation of CKD‐602. This study is the first to evaluate the factors affecting the high interpatient variability in the…”
Get full text

7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate by Jacobs, S A, Stoller, R G, Chabner, B A, Johns, D G

“…Human subjects and rhesus monkeys receiving the antitumor agent methotrexate at the high dose levels recently introduced into clinical use (greater than 50…”
Get full text

Intrahepatic platinum in the treatment of liver metastases from small cell lung cancer by Jacobs, S A, Santicky, M J, Earle, M F, Stoller, R G

Get more information

Phase I and pharmacokinetic (PK) study of dasatinib (D) and cetuximab (C) in patients (pts) with advanced solid malignancies by Feinstein, T. M., Agrawal, S., Stoller, R. G., Egorin, M. J., Argiris, A.

“…Abstract only 3540 Background: D is a small molecule inhibitor of several kinases, including SRC. SRC can potentiate Epidermal Growth Factor Receptor (EGFR)…”
Get full text

Safety and activity of IPI-504 (retaspimycin hydrochloride) and docetaxel in pretreated patients (pts) with metastatic non-small cell lung cancer (NSCLC) by Riely, G. J., Gettinger, S. N., Stoller, R. G., Gabrail, N. Y., Dy, G. K., Weiss, G. J., Tunkey, C., Skliris, G., Strychor, S., Dunbar, J., DeLucia, D., Ross, R. W., Gray, J. E.

“…Abstract only…”
Get full text

Random assignment multicenter phase II study of modified docetaxel, cisplatin, fluorouracil (mDCF) versus DCF with growth factor support (GCSF) in metastatic gastroesophageal adenocarcinoma (GE) by Shah, M. A., Shibata, S., Stoller, R. G., Kemeny, M., Ritch, P. S., Krishnamurthi, S. S., Su, Y. B., Janjigian, Y. Y., Capanu, M., Kelsen, D. P.

“…Abstract only…”
Get full text

Population pharmacokinetics of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced solid tumors by Wu, H., Ramanathan, R. K., Srychor, S., Zamboni, B. A., Ramalingam, S., Edwards, R. P., Friedland, D. M., Stoller, R. G., Belani, C. P., Zamboni, W. C.

“…Abstract only 2545 Background: CKD-602, a semi-synthetic analogue of campothecin, is a potent topoisomerase I inhibitor. S-CKD602, a PEGylated long-circulating…”
Get full text

Dose-dependent metabolism of methotrexate in man and rhesus monkeys by Jacobs, S A, Stoller, R G, Chabner, B A, Johns, D G

“…Humans and rhesus monkeys receiving high-dose methotrexate (MTX) (greater than 50 mg/kg) excrete significant quantities of the metabolite, 7-hydroxy-MTX. This…”
Get more information

Phase I trial of cetuximab (C) and dasatinib (D) in patients (pts) with advanced solid malignancies by Esteve, F. R., Stoller, R. G., Josephson, A., Grandis, J. R., Egorin, M. J., Argiris, A. E.

“…Abstract only…”
Get full text

Phase II study of RAD001 (Everolimus) in previously treated small cell lung cancer (SCLC) by Owonikoko, T. K., Stoller, R. G., Petro, D., Flaugh, R., Hershberger, P. A., Belani, C. P., Argiris, A. E.

“…Abstract only…”
Get full text

Clinical trial of weekly pyrazofurin by Cummings, F J, Stoller, R G, Calabresi, P

“…Pyrazofurin was administered to 21 patients with solid tumors at a dose of 200 mg/m2 iv weekly, because this dose had been shown to be well-tolerated and…”
Get more information

Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity by Stoller, R G, Hande, K R, Jacobs, S A, Rosenberg, S A, Chabner, B A

“…To correlate the pharmacokinetics and toxicity of methotrexate, we measured the drug's clearance from plasma after 395 high-dose, six-hour infusions given to…”
Get more information

Age and body composition related-effects on the pharmacokinetic disposition of STEALTH liposomal CKD- 602 (S-CKD602) in patients with advanced solid tumors by Zamboni, W., Maruca, L. J., Strychor, S., Zamboni, B. A., Ramalingam, S., Edwards, R. P., Friedland, D. M., Stoller, R. G., Belani, C. P., Ramanathan, R. K.

“…Abstract only 2528 Background: STEALTH liposomes (SL), which contain lipids conjugated to polyethylene glycol (PEG), prolong the circulation time of a drug in…”
Get full text

Final results of a phase I and pharmacokinetic study of STEALTH liposomal CKD-602 (S-CKD602) in patients with advanced solid tumors by Zamboni, W. C., Friedland, D. M., Ramalingam, S., Edwards, R. P., Stoller, R. G., Belani, C. P., Strychor, S., Ou, Y. C., Tonda, M. E., Ramanathan, R. K.

“…Abstract only 2013 Background: S-CKD602 is a pegylated STEALTH liposomal formulation of CKD-602, a semi-synthetic analogue of camptothecin (CPT) and…”
Get full text

Deoxycytidine kinase: properties of the enzyme from human leukemic granulocytes by Coleman, C N, Stoller, R G, Drake, J C, Chabner, B A

“…Deoxycytidine kinase, which phosphorylates deoxycytidine (CdR) and its analog, cytosine arabinoside (ara-C), has been purified 71-fold from human leukemic…”
Get full text

Deoxycytidine kinase: properties of the enzyme from human leukemic granulocytes by Coleman, CN, Stoller, RG, Drake, JC, Chabner, BA

“…Deoxycytidine kinase, which phosphorylates deoxycytidine (CdR) and its analog, cytosine arabinoside (ara-C), has been purified 71-fold from human leukemic…”
Get full text

Phase I and pharmacokinetic (PK) study of STEALTH liposomal CKD-602 (S-CKD602) in patients with advanced solid tumors by Zamboni, W. C., Ramalingam, S., Friedland, D. M., Belani, C. P., Stoller, R. G., Modi, N. B., Nath, R. P., Tonda, M. E., Strychor, S., Ramanathan, R. K.

“…Abstract only…”
Get full text

Abstract PD09-06: Two phase I trials exploring different dosing schedules of carboplatin (C), paclitaxel (P), and the poly-ADP-ribose polymerase (PARP) inhibitor, veliparib (ABT-888) (V) with activity in triple negative breast cancer (TNBC) by Puhalla, SL, Appleman, LJ, Beumer, JH, Tawbi, H, Stoller, RG, Owonikoko, TK, Ramalingam, SS, Belani, CP, Brufsky, AM, Abraham, J, Shepherd, SP, Giranda, V, Chen, AP, Chu, E

“…Abstract Background: The histopathologic and molecular similarities between TNBC and BRCA-1 mutation related breast cancer provide rationale for the use of…”
Get full text

A clinical and pharmacological study of high-dose methotrexate with minimal leucovorin rescue by Stoller, R G, Kaplan, H G, Cummings, F J, Calabresi, P

Get full text

Analysis of cytidine deaminase and tetrahydrouridine interaction by use of ligand techniques by Stoller, R G, Myers, C E, Chabner, B A

Get more information